Longwood Capital Partners »

Inhibrx Biosciences shares owned by Longwood Capital Partners

Quarter-by-quarter ownership of Inhibrx Biosciences (INBX) shares owned by Longwood Capital Partners from 13F filings

Historical chart of Longwood Capital Partners investment in Inhibrx Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Inhibrx Biosciences held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibrx Biosciences by Longwood Capital Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $552k 16k 33.68

More positions owned by Longwood Capital Partners

Ocular Therapeutix (OCUL)
Cidara Therapeutics Com New (CDTX)
Tourmaline Bio (TRML)
Aadi Bioscience (WHWK)
Insmed Com Par $.01 (INSM)
Bright Minds Biosciences Com New (DRUG)
Argen Se - Sponsored Adr (ARGX)
Amylyx Pharmaceuticals (AMLX)
Terns Pharmaceuticals (TERN)
Jazz Pharmaceuticals Shs Usd (JAZZ)
Compass Therapeutics (CMPX)
Praxis Precision Medicines I (PRAX)
Surrozen Com New (SRZN)
Ascendis Pha- Sponsored Adr (ASND)
Krystal Biotech (KRYS)

View all positions for Longwood Capital Partners

Top funds holding Inhibrx Biosciences

Viking Global Investors
Perceptive Advisors
Sanofi
HighTower Advisors
BlackRock
Vanguard Group
Sofinnova Ventures
Woodline Partners
Millennium Management
Partner Fund Management
Caligan Partners
Geode Capital Management
State Street Corporation
Readystate Asset Management
Kennedy Capital Management

View all funds holding Inhibrx Biosciences